Skip to main content
Clinical Trials/RBR-10myxdss
RBR-10myxdss
Not yet recruiting
未知

se of the patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE) short version and MDASI in patients with Cancer patients submitted to oral antineoplastic medications such as Tyrosine Kinase Inhibitors: a comparative study of the 2 scales

niversidade Federal de São Paulo0 sitesNovember 7, 2022

Overview

Phase
未知
Intervention
Not specified
Conditions
Adverse events
Sponsor
niversidade Federal de São Paulo
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
November 7, 2022
End Date
December 31, 2024
Last Updated
2 years ago
Study Type
Intervention

Investigators

Sponsor
niversidade Federal de São Paulo

Eligibility Criteria

Inclusion Criteria

  • older than 18 years; being treated with TKI alone as anticancer therapy, orally and for 3 months or more; being diagnosed with one of three cancers: kidney, lung, or chronic myeloid leukemia; Performance status between 0 and 2, evaluated according to the Eastern Cooperative Oncologic Group – ECOG scale

Exclusion Criteria

  • multiple comorbidities (3 or more), partial completion of one of the data collection instruments

Outcomes

Primary Outcomes

Not specified

Similar Trials